Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00003
|
|||||
Drug Name |
Lisdexamfetamine
|
|||||
Synonyms |
Lisdexamfetamine (INN); NRP104; Vyvanse (TN)
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Attention deficit hyperactivity disorder [ICD11: 6A05] | Approved | [1] | |||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C15H25N3O
|
|||||
Canonical SMILES |
CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N
|
|||||
InChI |
InChI=1S/C15H25N3O/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19)/t12-,14-/m0/s1
|
|||||
InChIKey |
VOBHXZCDAVEXEY-JSGCOSHPSA-N
|
|||||
CAS Number |
CAS 608137-32-2
|
|||||
Pharmaceutical Properties | Molecular Weight | 263.38 | Topological Polar Surface Area | 81.1 | ||
Heavy Atom Count | 19 | Rotatable Bond Count | 8 | |||
Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 3 | |||
XLogP |
1.2
|
|||||
PubChem CID | ||||||
PubChem SID | ||||||
ChEBI ID |
ChEBI:135925
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | PEPT1 | Transporter Info | Peptide transporter 1 | Substrate | [2] | |
References | ||||||
1 | Lisdexamfetamine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010 Jun 24;6:317-27. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.